Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27818544 | 0.92 | AGTR1 (0.41) | AGTR1AGTR2 | |
| SCHEMBL7015930 | 0.91 | AGTR1 (0.47) | AGTR1AGTR2 | |
| SCHEMBL7011057 | 0.90 | AGTR1 (0.46) | AGTR1AGTR2 | |
| SCHEMBL7009422 | 0.87 | AGTR1 (0.46) | AGTR1AGTR2 | |
| SCHEMBL684047 | 0.87 | PPARG (0.54) | AGTR1AGTR2 | |
| SCHEMBL12857056 | 0.87 | — | — | |
| SCHEMBL7016811 | 0.85 | AGTR1 (0.47) | AGTR1AGTR2 | |
| SCHEMBL7012683 | 0.84 | — | — | |
| SCHEMBL7015932 | 0.84 | ABCB11 (0.56) | AGTR1AGTR2 | |
| SCHEMBL7012638 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120302614-A1 | METHOD FOR IMPROVING CEREBRAL CIRCULATION OR TREATING A CEREBRAL BLOOD FLOW DISORDER | OSAKA UNIVERSITY (JP) | 2012-11-29 | — | — | US | claimed |
| US-20100130567-A1 | MEDICAL AGENT FOR PREVENTION OR TREATMENT OF ALZHEIMER 'S DISEASE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-05-27 | — | — | US | claimed |
| EP-2174666-A1 | MEDICINAL AGENT FOR PREVENTION OR TREATMENT OF ALZHEIMER'S DISEASE | Daiichi Sankyo Company, Limited (JP) | 2010-04-14 | — | — | EP | claimed |
| EP-0520423-B1 | Heterocyclic compounds, their production and use as angiotensin II antagonists | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2003-05-14 | — | — | EP | claimed |
| US-5583141-A | ADMINISTERING AS THERAPEUTIC AGENTS OF CIRCULATORY DISEASES; AZILSARTAN; ANGIOTENSIN II ANTAGONISTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-12-10 | — | — | US | claimed |
| EP-0520423-A2 | Heterocyclic compounds, their production and use as angiotensin II antagonists | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1992-12-30 | — | — | EP | claimed |
| US-20120302614-A1 | METHOD FOR IMPROVING CEREBRAL CIRCULATION OR TREATING A CEREBRAL BLOOD FLOW DISORDER | OSAKA UNIVERSITY (JP) | 2012-11-29 | — | — | US | disclosed |
| EP-1990052-B1 | PHARMACEUTICAL PACKAGE COMPRISING 2-ETHOXY-1-{[2'-(5-OXO-4,5-DIHYDRO-1,2,4-OXADIAZOL-3-YL)BIPHENYL-4-YL]METHYL}-1H-BENZIMIDAZOLE-7-CARBOXYLIC ACID (5-METHYL-2-OXO-1,3-DIOXOL-4-YL)METHYL OR 2-CYCLOPROPYL-1-{[2'-(5-OXO-4,5-DIHYDRO-1,2,4-OXADIAZOL-3-YL)BIPHENYL-4-YL]METHYL}-1H-BENZIMIDAZOLE-7-CARBOXYLIC ACID (5-METHYL-2-OXO-1,3-DIOXOL-4-YL)METHYL AND A DESICCANT. | TAKEDA PHARMACEUTICAL (JP) | 2012-05-16 | — | — | EP | disclosed |
| US-20100130567-A1 | MEDICAL AGENT FOR PREVENTION OR TREATMENT OF ALZHEIMER 'S DISEASE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-05-27 | — | — | US | disclosed |
| EP-2174666-A1 | MEDICINAL AGENT FOR PREVENTION OR TREATMENT OF ALZHEIMER'S DISEASE | Daiichi Sankyo Company, Limited (JP) | 2010-04-14 | — | — | EP | disclosed |
| US-20090012132-A1 | Pharmaceutical Package | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-01-08 | — | — | US | disclosed |
| EP-1990052-A1 | PHARMACEUTICAL PACKAGE | Takeda Pharmaceutical Company Limited (JP) | 2008-11-12 | — | — | EP | disclosed |
| EP-0520423-B1 | Heterocyclic compounds, their production and use as angiotensin II antagonists | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2003-05-14 | — | — | EP | disclosed |
| US-5639773-A | TREATING GLAUCOMA | SENJU PHARMACEUTICAL CO., LTD. (JP) | 1997-06-17 | — | — | US | disclosed |
| US-5583141-A | ADMINISTERING AS THERAPEUTIC AGENTS OF CIRCULATORY DISEASES; AZILSARTAN; ANGIOTENSIN II ANTAGONISTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-12-10 | — | — | US | disclosed |
| WO-1995001176-A1 | USE OF AN ANGIOTENSIN II ANTAGONIST AS AN OCULAR HYPOTENSIVE AGENT | SENJU PHARMACEUTICAL CO., LTD. (JP) | 1995-01-12 | — | — | WO | disclosed |
| EP-0631780-A1 | Use of an angiotensin II antagonist as an ocular hypotensive agent | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1995-01-04 | — | — | EP | disclosed |
| US-5354766-A | 2-Ethoxy-1-((2'(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl) biphenyl-4-yl)methyl)benzimidazole-7-carboxylic acid; hypotensive agents; CNS activity | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-10-11 | — | — | US | disclosed |
| US-5243054-A | Hypotensive agents, cardiovascular disorders or nervous system disorders | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-09-07 | — | — | US | disclosed |
| EP-0520423-A2 | Heterocyclic compounds, their production and use as angiotensin II antagonists | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1992-12-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130567-A1 | MEDICAL AGENT FOR PREVENTION OR TREATMENT OF ALZHEIMER 'S DISEASE | AGTR1, AGTR2, ACE | AGTR1 1/4885AGTR2 2/4885 |
| US-20120302614-A1 | METHOD FOR IMPROVING CEREBRAL CIRCULATION OR TREATING A CEREBRAL BLOOD FLOW DISORDER | AGTR2, AGTR1, BDKRB2 | AGTR1 2/4885AGTR2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.